Complex Mental Illness and Concurrent Addictions
|
|
- Frank Lester
- 6 years ago
- Views:
Transcription
1 Complex Mental Illness and Concurrent Addictions Tony P. George, M.D., FRCPC Professor of Psychiatry Co Director, Division of Brain and Therapeutics Department of Psychiatry, University of Toronto Chief, Schizophrenia Division Medical Director, Complex Mental Illness Program Centre for Addiction and Mental Health (CAMH) Toronto, Ontario, Canada M5T 1R8
2 Disclosures: Dr. Tony P. George Advisory board or similar committee Novartis, Pfizer Honoraria or other fees Pfizer, Novartis, Janssen, ACNP (Deputy Editor, Neuropsychopharmacology) Research grants NIH/NIDA, NARSAD, CIHR, Canada Foundation for Innovation (CFI), Ontario Mental Health Foundation (OMHF), Pfizer Global Research
3 Learning objectives Discuss reasons for the high rates of substance use disorders among people with serious mental illness. Describe evidence-based treatments, including pharmacological and behavioural interventions. Describe an integrated treatment approach to concurrent addictions in serious mental illness.
4
5 Addictions in the News
6 Concurrent Disorders = Heterogeneity Schizophrenia Alcohol Use Disorder Major Depression Cocaine Use Disorder Bipolar Disorder Tobacco Use Disorder PTSD Borderline Personality Disorder Cannabis Use Disorder Pathological Gambling
7 Case Review Mr. A., a 34 year old single Caucasian male diagnosed with schizophrenia, presented to a community mental health center for treatment of psychosis, and cocaine dependence. He was reportedly spending ~$2,000 per month, and driving more than 30 minutes from his home to obtain crack cocaine; he used cocaine in a binge pattern every 2 3 days. On several occasions, he had shown up at his mother s work place and harassed her for money, and security had to be called. The mother never pressed charges. He presented with increasing paranoia, command auditory hallucinations, and thought broadcasting. Mr. A reports severe cocaine cravings every 1 2 days when not using, and stated that he smokes crack cocaine (1 2 rocks/session) to make him feel normal and give him a sense of calmness. However, he admitted that using cocaine makes him more paranoid and irritable. He has intermittent thoughts of suicide.
8 Crack Pipe
9 Cocaine Misusing Schizophrenia Patients and Disability Income Shaner et al. (1995) from UCLA studied the relationship between disability payments and cocaine use, psychiatric symptoms and hospitalization rates at three day intervals during a month in male veteran cocaine addicts with schizophrenia in Los Angeles.
10
11
12
13 Factors Associated with Addiction Vulnerability Genetic/Familial Stress Gender Personality Factors Cognitive Impulsivity, Executive Function Psychiatric Disorders Adverse Childhood Events (ACE; including, verbal, physical and sexual abuse, household drug use)
14 Cause of Disability in the United States, Canada, and Western Europe in 2000 Mental illnesses Alcohol and drug use disorders Alzheimer s disease and dementias Musculoskeletal diseases Respiratory diseases Cardiovascular diseases Sense organ diseases Injuries (disabling) Digestive diseases Communicable diseases Cancer (malignant neoplasms) Diabetes Migraine All other causes of disability >36% of disability attributed to mental illness plus addictions!! Proportion of Cases of Disability (%) Data are from the report by the President s New Freedom Commission on Mental Health (2003)
15 Co-morbidity of SUDs in Psychiatric Disorders (ECA Study) Any Alcohol/Drug AnyAlcohol Any Drug % Co-Morbidity Schizophrenia Depression Bipolar Disorder Phobias Panic Disorder ASPD Psychiatric Diagnosis Regier et al. (1990)
16 Prevalence of Smoking in Clinical Samples of Persons with Psychiatric and Substance Use Disorders Schizophrenia Bipolar Disorder Major Depression Panic Disorder Post-Traumatic Stress Disorder Alcohol Dependence Cocaine Dependence Opioid Dependence General U.S. Population General Canadian Population Mean Smoking Prevalence (%) PD SUD Non-PD Clinical Group From Morisano, D., Bacher, I. et al. (2009). Can. J. Psychiatry. 54:
17 SUDs in Schizophrenia Earlier onset of schizophrenia 1 2 Increased relapse 3 5 Treatment non compliance 6 1. Humbrecht, Häfner Biol Psychiatry, 1996;40: Tsuang et al. Arch Gen Psychiatry. 1982;39(2): Richard et al. J Clin Psychiatry. 1985;46(3): Gupta et al. Schizophr Res. 1996;20(1 2): Drake, Brunette. Recent Dev Alcohol. 1998;14: Owen et al. Psychiatr Serv. 1996;47(8):
18 SUDs in Schizophrenia (cont.) Poorer overall response to antipsychotic medication 1 More hospitalizations 2 3 Increased risk for violence 4 6 Increased medical costs 1. Bowers et.al. Schizophr Bull. 1990;16(1): Richard et.al. J Clin Psychiatry. 1985;46(3): Brady et.al. Am J Psychiatry. 1990;147(9): Swanson et.al. Hosp Comm Psychiatry. 1990;41(7): Dickey, Azeni. Am J Public Health. 1996;86(7): Fazel, S. JAMA. 2009; 301:
19 Schizophrenia, Substance Abuse and Violent Crime Fazel, S. et al. (2009). JAMA. 301:
20 Reasons to Explain Co-morbid SUDs in Schizophrenia Self-Medication Medication (e.g. to reduce psychiatric symptoms, medication side effects, boredom) Addiction Vulnerability Hypothesis - Shared genes or brain abnormalities which cause or make people vulnerable to mental illness and substance abuse Social and Environmental Factors poverty, drug availability, peer modeling Khantzian, 1997; Chambers et al., 2001; George, 2007; Bridgman et al., 2013
21
22 Two Models of Addiction in Schizophrenia Chambers, R.A. et al. (2001). Biol. Psychiatry
23 Neurocircuits Involved In Drug Dependence VTA
24 History Taking 1 What substance(s)? frequent polysubstance misuse in psychosis NB: Drugs which fuel psychosis stimulants (cocaine), cannabis, psychedlics (LSD), arylcyclohexylamines (PCP, ketamine), alcohol Most common Tobacco and Cannabis Age of first use Amount taken during a use episode (dollars spent) Route of administration (oral, snorted, IV, smoked) Consequences associated with use Time taken to recover from acute use
25 History Taking 2 Abstinence periods associated factors History of treatment Relapse what factors associated with this? Onset of SUD in relation to MH symptoms Impact of abstinence/reduction on MH symptoms Collateral contacts Motivation to reduce or stop drug use
26
27 Influence of adolescent-onset cannabis use on adult psychosis is moderated by allelic variations in the Catecholamine O-Methyltransferase (COMT) gene (Caspi et al., Biol. Psychiatry)
28 Behavioural Treatments
29 Psychosocial Therapies for CD Motivational Interviewing (Martino et al., 2000) Cognitive Behavioural Therapies (Barraclough et al., 2001; Weiss et al., 2007) Contingency Management (Roll et al., 2004) Mindfulness Based Therapies
30 Evidence-Based Treatment Using Motivational Interviewing for CD Patients Martino et al. (2000). Am. J. Addictions. A single MI session versus a standard interview in 23 CD/SPMI patients led to improved substance abuse outcomes, treatment participation and medication compliance.
31 Integrated Group Therapies (IGT) Bipolar Substance Abusers Weiss, R.D. et al. (2007). Am. J. Psychiatry. 164: IGT addresses both Bipolar Disorder symptoms and co morbid drug and alcohol misuse. 20 week trial of IGT (n=31) vs. Group DC (n=31) in bipolar drug abusers.
32 Integrated Group Therapies Bipolar Substance Abusers IGT superior to GDC on drug and alcohol use, use to intoxication, time to first month of abstinence.
33 Integrated Group Therapy versus Group Drug Counseling For Bipolar Substance Abusers
34 Pharmacological Treatments
35 Pharmacotherapies Used to Treat Addictive Disorders Addictive Substance or Potential for Addiction Heroin Alcohol Nicotine Cocaine c Potential for cannabinoid, cocaine or alcohol addiction Medication Naltrexone a, Methadone a, Buprenorphine a Naltrexone a, Acamprosate a, Disulfiram a, Topiramate b Bupropion a, NRT a, Varenicline a Disulfiram b, Topiramate b, Modafinil b, Propranolol b, Baclofen b Rimonabant, Ondansetron, Topiramate a Approved by the Food and Drug Administration (FDA) for this indication b Approved by the FDA for another indication. c No medication is currently approved by the FDA for this indication. Adapted from O Brien, CP. Am. J. Psychiatry, 2005
36 Two Empirical Approaches to Pharmacotherapy of SUDs in Schizophrenia 1) Adjunctive treatment with an agent with antiaddictive drug effects (e.g. naltrexone, disulfiram, acamprosate, topiramate) 2) Treatment of the co morbid psychiatric disorder with an agent that may secondarily target the drug of abuse (e.g. antidepressants, atypical antipsychotic drugs)
37 Evidence-Based Pharmacotherapies for SUDs in Schizophrenia Atypical Antipsychotic Drugs for alcohol and stimulant dependence in schizophrenia (e.g., Albanese et al., 1994; McEvoy McEvoy et al., 1995; Drake et al., 2000; George et al., 2000; 2002). Naltrexone for Alcohol Abuse in Schizophrenia (e.g., Petrakis et al., 2004) Varenicline for Smoking Cessation in Schizophrenia (Pachas Pachas et al., 2011; Williams et al., 2012)
38 Pharmacotherapy for Comorbid Substance Use Disorder in Patients with Schizophrenia Naturalistic longitudinal study (N=101) Dual diagnosis, treatmentrefractory patients 36 patients given clozapine on clinical basis All patients prospectively assessed Drake, R.E. et al. Schiz. Bull % remission of alcohol abuse 0 79% 33% Clozapine Typical neuroleptic
39 Naltrexone for Alcohol Abuse in Schizophrenia Double blind, placebo controlled, randomized 12 week trial of naltrexone (50 mg/d) in N=31 patients with schizophrenia and alcoholism maintained on antipsychotic therapy. Behavioural platform of CBT and skills training. Naltrexone (versus placebo) reduced # of drinking days, # heavy drinking days, and alcohol craving. No published studies with the glutamate/gaba agent acamprosate Petrakis, IL et al. (2004). Psychopharmacology
40 Williams, J.M. et al. (2012). J. Clin. Psychiatry. 73: Varenciline for Smoking Cessation in People with Schizophrenia
41 Problems in the Care of People with CMI and Concurrent Disorders Non adherence to treatment Clinicians trained in treatment of psychiatric or addictive disorders but not both Lack of integrated treatment (e.g. patients get psychiatric treatment separate from that for addictions) Little research to support empirically validated treatment in co morbid populations Most co morbid patients don t achieve drug abstinence
42 Integrated Treatment Programs
43 Concurrent Disorders (CD) Severity Grid High MH, Low SUD Severity (Psychiatric Treatment Setting) High MH, High SUD Severity (Specialized CD Treatment Setting) Mental Health Severity Low MH, Low SUD Severity (Community Treatment) Low MH, High SUD Severity (Addictions Treatment Setting) Addiction Severity
44 Characteristics of Integrated Treatment Programs for Concurrent Disorders Client participates in ONE program that treats both PD and SUD. Both the PD and SUD are treated by the same clinician, who is trained in psychopathology, assessment and treatment of both disorders Drake, R.E. et al., Schizophr. Bull.
45 Characteristics of Integrated Treatment Programs for Concurrent Disorders SUD Treatment is tailored to those with SPMI. There is an adaptation of traditional abstinenceoriented SUD treatment to include SUD reduction oriented approaches. Drake et al., Schizophr. Bull.
46 Conclusions High rates of SUD co morbidity in people with psychiatric disorders, leads to significant disability and poor outcomes. Biopsychosocial vulnerability factors may explain this co morbidity.
47 Conclusions Treatments for this co morbidity should take advantage of the pathophysiological relationships between drug addiction and mental illness. Integrated psychiatric and SUD treatment is the evidence based standard of care for people with concurrent disorders.
48
Mood Disorders and Addictions: A shared biology?
Mood Disorders and Addictions: A shared biology? Dr. Paul Stokes Clinical Senior Lecturer, Centre for Affective Disorders, Department of Psychological Medicine Disclosures No relevant disclosures: No paid
More informationIntro to Concurrent Disorders
CSAM-SCAM Fundamentals Intro to Concurrent Disorders Presentation provided by Jennifer Brasch, MD, FRCPC Psychiatrist, Concurrent Disorders Program, St. Joseph s Healthcare There are all kinds of addicts,
More informationPrepared by: Dr. Elizabeth Woodward, University of Toronto Resident in Psychiatry
Prepared by: Dr. Elizabeth Woodward, University of Toronto Resident in Psychiatry In broad terms, substance use disorders occur when a substance is used in a compulsive manner with a lack of control over
More informationSmoking Cessation. Disclosures. Thank You. None
Smoking Cessation Dr. Jamie Kellar; BSc, BScPhm, PharmD Clinician Educator Centre for Addiction and Mental Health Assistant Professor Leslie Dan Faculty of Pharmacy Disclosures None Thank You Several slides
More informationTreatment Outcomes from the TDC: A Look at Smoking Cessation Among Patients with Co- Occurring Disorders
University of Kentucky From the SelectedWorks of Chizimuzo T.C. Okoli December, 2010 Treatment Outcomes from the TDC: A Look at Smoking Cessation Among Patients with Co- Occurring Disorders Chizimuzo T.C.
More informationTerminology. ECA Study. Studies on Co morbidity Most widely cited studies: Dual dx MICA CAMI Co Morbid Disorders Co Occurring Disorders
Psychiatric Co Morbidities Jeffrey Selzer, MD, FASAM Associate Professor of Psychiatry Hofstra North Shore LIJ School of Medicine Albert Einstein College of Medicine Medical Director, NYS Committee for
More informationConcurrent Disorders
Concurrent Disorders Dr. Christy Sutherland MD CCFP dipabam Medical Director, PHS Community Services Methadone/Buprenorphine 101 Workshop April 1, 2017 Overview Introduction Epidemiology Treatment Principles
More informationPsychopharmacology Practice Guidelines For Individuals With Co-Occurring Substance Abuse (SA) And Serious Mental Illness (SMI)
Psychopharmacology Practice Guidelines For Individuals With Co-Occurring Substance Abuse (SA) And Serious Mental Illness (SMI) Overview The results of the most recent national household survey found that
More informationDr. Meldon Kahan. Women s College Hospital. with PIA LAW
with PIA LAW and Toronto ABI Network Dr. Meldon Kahan Women s College Hospital Dr. Meldon Kahan is an Associate Professor in the Department of Family Medicine at University of Toronto, and Medical Director
More informationMedical Management of Substance Use Disorders: Does research translate to clinical practice
Medical Management of Substance Use Disorders: Does research translate to clinical practice Ashwin A Patkar, MD Professor of Psychiatry & Community & Family Medicine Duke University Medical Center Durham,
More informationRECOMMENDATIONS FOR HEALTH CARE PROVIDERS
Ending Addiction Changes Everything RECOMMENDATIONS FOR HEALTH CARE PROVIDERS CRITICAL ADDICTION PREVENTION, TREATMENT AND MANAGEMENT SERVICES TO INCLUDE IN ROUTINE HEALTH CARE PRACTICE JULY 2013 In the
More informationADHD & Addictions -What We Know
ADHD & Addictions -What We Know Dr. David Teplin, Psy.D., C.Psych. 4th CADDAC Annual Conference, Toronto October 14, 2012 1 Introduction Adult ADHD commonly co-exists with several other disorders, including
More informationPOLYSUBSTANCE USE IN THE TREATMENT OF OPIOID USE DISORDER WITH BUPRENORPHINE
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences POLYSUBSTANCE USE IN THE TREATMENT OF OPIOID USE DISORDER WITH BUPRENORPHINE MARK DUNCAN, MD November 8, 2018 SPEAKER
More information2018/05/01 DISCLOSURE EFFECTS OF CANNABIS USE IN ADOLESCENTS
DISCLOSURE EFFECTS OF CANNABIS USE IN ADOLESCENTS No conflict of interest to declare No pharmaceutical industry support No support from cannabis producers Selene Etches MD, FRCPC Cannabis is the most widely
More informationPharmacotherapy of Substance Use Disorders in Children and Adolescents: Special Considerations
Pharmacotherapy of Substance Use Disorders in Children and Adolescents: Special Considerations Dr. Ajeet Sidana Department of Psychiatry Government Medical College & Hospital Chandigarh Scope of Presentation
More informationCondensed Clinical Practice Guideline Treatment Of Patients With Schizophrenia
Condensed Clinical Practice Guideline Treatment Of Patients With Schizophrenia I. Key Points a. Schizophrenia is a chronic illness affecting all aspects of person s life i. Treatment Planning Goals 1.
More informationMain Questions. Why study addiction? Substance Use Disorders, Part 1 Alecia Schweinsburg, MA Abnromal Psychology, Fall Substance Use Disorders
Substance Use Disorders Main Questions Why study addiction? What is addiction? Why do people become addicted? What do alcohol and drugs do? How do we treat substance use disorders? Why study addiction?
More informationTreatment of Tobacco and Cocaine Use Disorders
Treatment of Tobacco and Cocaine Use Disorders A. Eden Evins, MD, MPH Director, Center for Addiction Medicine Massachusetts General Hospital Associate Professor of Psychiatry Harvard Medical School A.
More informationREVIEW ARTICLE MANAGEMENT OF PATIENTS WITH MOOD DISORDERS AND COMORBID SUDS
MANAGEMENT OF PATIENTS WITH MOOD DISORDERS AND COMORBID SUDS ANNALS OF CLINICAL PSYCHIATRY 2012;24(1):38-55 REVIEW ARTICLE The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations
More informationMedication Assisted Treatment of Substance Use Disorders
3 rd Annual Challenges & Innovations in Rural Psychiatry Conference Medication Assisted Treatment of Substance Use Disorders June 22, 2016 Medication Assisted Treatment of Substance Use Disorders Richard
More informationBipolar Disorder Clinical Practice Guideline Summary for Primary Care
Bipolar Disorder Clinical Practice Guideline Summary for Primary Care DIAGNOSIS AND CLINICAL ASSESSMENT Bipolar Disorder is categorized by extreme mood cycling; manifested by periods of euphoria, grandiosity,
More informationSmoking cessation and reduction in people with chronic mental illness
Link to this article online for CPD/CME credits Smoking cessation and reduction in people with chronic mental illness Center for Alcohol and Addiction Studies, Brown University, Providence, RI 02912, USA
More informationDr. Oslin receives grant support from the NIH, VA, and the Pennsylvania Department of Aging.
David W. Oslin, MD University of Pennsylvania Philadelphia VAMC Dr. Oslin receives grant support from the NIH, VA, and the Pennsylvania Department of Aging. Dr. Oslin is a consultant to the Hazelden Betty
More informationMedication Assisted Treatment. Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs
Medication Assisted Treatment Karen Drexler, MD National Mental Health Program Director-Substance Use Disorders Department of Veterans Affairs Disclosures Employed by the Department of Veterans Affairs
More informationPage 1. Pharmacologic Interventions for. Addictions. Objectives for This Talk. Outline for This Talk
Pharmacologic Interventions for Addictions Eric C. Strain, M.D. Johns Hopkins University School of Medicine, Baltimore, Maryland Maryland Psychiatric Society November 7, 2015 Objectives for This Talk I.
More informationPharmacologic Interventions for. Addictions
Pharmacologic Interventions for Addictions Eric C. Strain, M.D. Johns Hopkins University School of Medicine, Baltimore, Maryland Maryland Psychiatric Society November 7, 2015 Objectives for This Talk I.
More informationTHE STATE OF MEDICINE IN ADDICTION RECOVERY
OVERVIEW: Review addiction stats and trends Define addiction Explain neurobiology of addiction Review treatments of addiction Addiction Definition: A Primary, chronic, relapsing disease of brain reward,
More informationYouth, Opioid Use and Treatment Options. CPSO MMT Providers Conference Dr. Sharon Cirone MD FCFPC November 2016
Youth, Opioid Use and Treatment Options CPSO MMT Providers Conference Dr. Sharon Cirone MD FCFPC November 2016 Disclosures No propriety involvement in pharmaceutical companies Assessor, CPSO Methadone
More informationObjectives 11/2/2016. Managing Patients with Substance Abuse. Off Label Disclosure. Steven Shoptaw, PhD Professor Department of Family Medicine, UCLA
Managing Patients with Substance Abuse Steven Shoptaw, PhD Professor Department of Family Medicine, UCLA Objectives Epidemiology: Substances most likely to be misused in HIV care settings. Diagnostic and
More informationMedication-Assisted Treatment and HIV/AIDS: Aspects in Treating HIV- Infected Drug Users.
Slide #1 Medication-Assisted Treatment and HIV/AIDS: Aspects in Treating HIV- Infected Drug Users. R. Douglas Bruce, MD, MA, MSc Assistant Professor Yale AIDS Program Medical Director South Central Rehabilitation
More informationVOLUME C. Pharmacological Treatment for Drug Use Disorders Drug Treatment for Special Populations
VOLUME C Pharmacological Treatment for Drug Use Disorders Drug Treatment for Special Populations VOLUME C MODULE 1 MODULE 2 MODULE 3 Dependence Basics Basics of Opioid Special Populations: Dependence.
More informationBuilding capacity for a CHC response to Ontario's Opioid Crisis
Building capacity for a CHC response to Ontario's Opioid Crisis Rob Boyd Oasis Program Director Luc Cormier, RN, MScN Community Health Nurse Sandy Hill Community Health Centre #AOHC2016 @rboyd6 @SandyHillCHC
More informationAssessment and Management of Co-Occurring Psychiatric Illnesses During Office-Based Opioid Treatment
Assessment and Management of Co-Occurring Psychiatric Illnesses During Office-Based Opioid Treatment Joji Suzuki, MD Assistant Professor of Psychiatry Harvard Medical School Director, Division of Addiction
More informationPharmacological Treatments for Tobacco Users with Behavioral Health Conditions
Pharmacological Treatments for Tobacco Users with Behavioral Health Conditions Jill M Williams, MD Professor Psychiatry Director, Division Addiction Psychiatry Robert Wood Johnson Medical School Disclosures
More informationMEDICATION ASSISTED ADDICTION TREATMENT: Appropriate Use
MEDICATION ASSISTED ADDICTION TREATMENT: Appropriate Use Louis E. Baxter, Sr., M.D., DFASAM Executive Medical Director-PAPNJ Assistant Clinical Professor Medicine Rutgers New Jersey Medical School DMHAS-Addiction
More informationProgram Topics Offered by the Office of Education and Regional Programming/Western Psychiatric Institute and Clinic through June 2011
Program Topics Offered by the Office of Education and Regional Programming/Western Psychiatric Institute and Clinic through June 2011 Children and Adolescents ASSUMING THE PARENTAL ROLE WITHIN THE FAMILY:
More information8/5/2013. MOSBIRT Annual Training The Big change in addiction medicine? Before we dive into pharmacotherapy
Medication Assisted Treatment for Substance Abuse in Primary Care Dan Vinson August 1, 2013 1 The Big change in addiction medicine? These diseases are rapidly becoming medical diseases. Done are the days
More informationThe 5A's are practice guidelines on tobacco use prevention and cessation treatment (4):
Smoking Cessation Module Tobacco use is the single greatest preventable cause of chronic diseases and premature deaths worldwide. The Canadian Cancer Society reports that tobacco product use is responsible
More informationTreating Addiction as a Chronic Disease
Treating Addiction as a Chronic Disease Sarah E. Wakeman, MD, FASAM Medical Director, MGH Substance Use Disorder Initiative Assistant Professor of Medicine, Harvard Medical School Disclosures Neither I
More informationTHE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE. Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept.
THE MEDICAL MODEL: ADDICTION IS A BRAIN DISEASE Judith Martin, MD Medical Director of Substance Use Services San Francisco Dept. Public Health disclosures Dr. Martin has no conflict of interest to disclose.
More informationSubstance Use and Mental Health: Applications of the interrai Mental Health Suite
Substance Use and Mental Health: Applications of the interrai Mental Health Suite Christopher Perlman, PhD Assistant Professor, University of Waterloo Waterloo, Ontario, Canada Fellow, interrai April 20,
More informationDialectical Behaviour Therapy in an Outpatient Drug and Alcohol Setting
Dialectical Behaviour Therapy in an Outpatient Drug and Alcohol Setting Distinguishing features of DBT Implementing DBT within Drug Health Services RPAH Case Study Background to DBT Developed in early
More informationAlberta Alcohol and Drug Abuse Commission. POSITION ON ADDICTION AND MENTAL HEALTH February 2007
Alberta Alcohol and Drug Abuse Commission POSITION ON ADDICTION AND MENTAL HEALTH POSITION The Alberta Alcohol and Drug Abuse Commission (AADAC) recognizes that among clients with addiction problems, there
More informationUnderstanding and Treating Behavioral Addictions
Understanding and Treating Behavioral Addictions Jon Grant, MD, JD, MPH Professor of Psychiatry and Behavioral Neuroscience University of Chicago Chicago, Illinois Disclosure The faculty have been informed
More informationReview: Psychosocial assessment and theories of development from N141 and Psych 101
Unit III Theory and Practice of Psychiatric Nursing REQUIRED READINGS AND ACTIVITIES Related Activities Assignments Review: Psychosocial assessment and theories of development from N141 and Psych 101 Anxiety,
More informationSupporting smokers with mental health problems
Collaboration for Leadership in Applied Health Research and Care South London (CLAHRC South London) Supporting smokers with mental health problems Ann McNeill, Professor of Tobacco Addiction Dr Debbie
More informationWISAM 2018 Annual Conference Sept , PTSD and Substance Use Disorder in Veterans 9/28/2018. PTSD and SUD
PTSD and Substance Use Disorder in Veterans Todd J Kammerzelt, MD General and Addiction Psychiatrist 9/28/2018 PTSD and SUD More than 1 in 4 veterans with PTSD also have SUD War Veterans with PTSD and
More informationMethamphetamine & Cocaine Use Disorders
Methamphetamine & Cocaine Use Disorders Timothy E. Wilens, MD Director, Center for Addiction Medicine Chief, Division of Child and Adolescent Psychiatry, Massachusetts General Hospital Harvard Medical
More informationCourse Catalog. Early Intervention, Treatment, and Management of Substance Use Disorders
Course Catalog To take a course, visit our website at https://www.mindfulceus.com - You can link directly to a course by visiting https://www.mindfulceus.com/course/id where ID is the ID number listed
More information10 INDEX Acknowledgements, i
INDEX 10 INDEX Acknowledgements, i Acute Care, Admissions to, 3.83 Discharge Planning, 3.86 Involuntary Admission Criteria, 3.84 List of Designated Provincial and Regional Mental Health Facilities, 3.83
More informationSchizophrenia: Early Intervention
Focus on CME at The University of Western Ontario Schizophrenia: Early Intervention Rahul Manchanda, MD, MRCPsych, FRCP(C); and Ross M.G. Norman, PhD, CPsych Presented at A Psychiatric Update 2003, Regional
More informationSchizophrenia and comorbid cannabis use disorders: Brain structure, function and the effect of antipsychotic medications Machielsen, Marise
UvA-DARE (Digital Academic Repository) Schizophrenia and comorbid cannabis use disorders: Brain structure, function and the effect of antipsychotic medications Machielsen, Marise Link to publication Citation
More informationBest Practice Workgroup Considerations. New Jersey Shared Values: Unified Child Welfare Practice Conference April 29, 2011
New Jersey Shared Values: Unified Child Welfare Practice Conference April 29, 2011 Evidence-based and Innovative Treatment Models: Setting the Stage for our Discussions Best Practice Workgroup Considerations
More informationComorbidity of Substance Use Disorders and Psychiatric Conditions-2
Comorbidity of Substance Use Disorders and Psychiatric Conditions-2 J. H. Atkinson, M.D. Professor of Psychiatry HIV Neurobehavioral Research Programs University of California, San Diego KETHEA, Athens,
More informationAcute General Medical and Surgical Admission:
Acute General Medical and Surgical Admission: Managing Substance Use Disorders in Patients Who are Severely Ill Scott Grantham, MD Executive Director, Behavioral Health Saint Francis Health System By the
More informationEMERGING ISSUES IN SMOKING CESSATION
EMERGING ISSUES IN SMOKING CESSATION Andrew Pipe, CM, MD Chief, Division of Prevention & Rehabilitation University of Ottawa Heart Institute Faculty/Presenter Disclosure Andrew Pipe, CM, MD University
More informationDr. Renner receives honoraria from Reed Medical Education
Substance Use Disorders Symposium on Men s Health Massachusetts Medical Society June 17, 2010 John A. Renner, Jr., M.D. John A. Renner Jr., MD DISCLOSURES Johnson & Johnson Stock Holder Dr. Renner receives
More informationTobacco Use and Reproductive Health: An Update
Project with Alberta Health Services Christene Fetterly Gail Foreman and Tasha Allen Tobacco Use and Reproductive Health: An Update Lorraine Greaves PhD Nancy Poole PhD Natalie Hemsing, Research Associate,
More informationGOALS FOR THE PSCYHIATRY CLERKSHIP
GOALS FOR THE PSCYHIATRY CLERKSHIP GOALS - The aim of the core psychiatry clerkship is to expose students to patients with mental illness and to prepare them to provide psychiatric care at a basic level.
More informationTreatment Approaches for Drug Addiction
Treatment Approaches for Drug Addiction NOTE: This fact sheet discusses research findings on effective treatment approaches for drug abuse and addiction. If you re seeking treatment, you can call the Substance
More informationResearch & Treatment of Persons with SUDS & Psychotic Disorders
Research & Treatment of Persons with SUDS & Psychotic Disorders Kim T. Mueser, Ph.D. Professor of Psychiatry Dartmouth Medical School Kim.t.mueser@dartmouth.edu NIDA Blending Conference April 22, 2010
More information9/16/2016. I would feel comfortable dispensing/prescribing varenicline to a patient with a mental health disorder. Learning Objectives
The Smoking Gun: for Smoking Cessation in Patients with Mental Health Disorders BRENDON HOGAN, PHARMD PGY2 PSYCHIATRIC PHARMACY RESIDENT CTVHCS, TEMPLE, TX 09/23/2016 I would feel comfortable dispensing/prescribing
More informationTobacco treatment for people with serious mental illness (SMI)
Tobacco treatment for people with serious mental illness (SMI) An opportunity to close the mortality gap Massachusetts Mental Health Center 1 National Resource Center for Academic Detailing A compelling
More informationTeen Mental Health and Substance Abuse. Cheryl Houtekamer AHS - AADAC Youth Services Calgary
Teen Mental Health and Substance Abuse Cheryl Houtekamer AHS - AADAC Youth Services Calgary Agenda Me? Talk about mental health?? Adolescent development Brain development Adolescent drug use Mental health
More informationHelping People Quit Tobacco
Helping People Quit Tobacco Peter Selby MBBS, CCFP, MHSc, ASAM Associate Professor, University of Toronto Clinical Director, Addictions Program, CAMH Principal Investigator, OTRU Disclosures! Grants/research
More informationIPAP Cocaine Dependence Algorithm
IPAP Cocaine Dependence Algorithm page 1 of 7 Overall context and level of evidence When selecting pharmacotherapies for stimulant dependence, one must keep in mind that there are no medications that have
More information9/12/2012 ALCOHOL AND DRUG USE, ASSOCIATED DISORDERS AND THEIR PSYCHIATRIC COMORBIDITIES IN U.S. ADULTS OBJECTIVES
ALCOHOL AND DRUG USE, ASSOCIATED DISORDERS AND THEIR PSYCHIATRIC COMORBIDITIES IN U.S. ADULTS Risë B. Goldstein, Ph.D., M.P.H., Staff Scientist Laboratory of Epidemiology and Biometry Division of Intramural
More informationPersonality disorders as predictors of treatment outcome in a sample of alcohol dependent veterans with comorbid axis I disorders
Washington University School of Medicine Digital Commons@Becker Posters 2005: Alcoholism and Comorbidity 2005 Personality disorders as predictors of treatment outcome in a sample of alcohol dependent veterans
More informationPharmacotherapy of Alcohol Use Disorders
Pharmacotherapy of Alcohol Use Disorders Roger D. Weiss, MD Professor of Psychiatry, Harvard Medical School Chief, Division of Alcohol and Drug Abuse McLean Hospital rweiss@mclean.harvard.edu Consultant
More informationMental Health and Behavioral Health
Mental Health and Behavioral Health mpfc (AC) Insula Thal DS GP VS VS VTA VTA Hippo OFC Wilson M. Compton, M.D., M.P.E. Deputy Director National Institute on Drug Abuse Advancing Addiction Science Behavioral
More informationThe future of pharmacological treatment.
The future of pharmacological treatment. Anne Lingford-Hughes Professor of Addiction Biology, Imperial College. Hon Consultant CNWL NHS Foundation Trust. What substances and when? What Nicotine Alcohol
More informationSUBSTANCE USE DISORDER IN ADOLESCENT POPULATION
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences SUBSTANCE USE DISORDER IN ADOLESCENT POPULATION ANNABELLE SIMPSON, MD UNIVERSITY OF WASHINGTON GENERAL DISCLOSURES
More informationTreatment of Tobacco and Cocaine Use Disorders
Treatment of Tobacco and Cocaine Use Disorders A. Eden Evins, MD, MPH Director, Center for Addiction Medicine Massachusetts General Hospital Associate Professor of Psychiatry Harvard Medical School A.
More informationTony Klein, MPA, CASAC, NCACII
Tony Klein, MPA, CASAC, NCACII Presentation Overview Tobacco Dependence in Individuals with Co-occurring Addictions Challenges and Barriers Organizational Change Strategies Program & System Changes to
More informationComorbidity With Substance Abuse P a g e 1
Comorbidity With Substance Abuse P a g e 1 Comorbidity With Substance Abuse Introduction This interesting session provided an overview of recent findings in the diagnosis and treatment of several psychiatric
More informationTreatment Outcomes of a Tailored Smoking Cessation Programme for Individuals Accessing Addiction Treatment Services
University of Kentucky UKnowledge Nursing Presentations College of Nursing 6-2012 Treatment Outcomes of a Tailored Smoking Cessation Programme for Individuals Accessing Addiction Treatment Services Milan
More informationDepression often comorbid with alcohol dependence 1.6x higher rate of alcohol dependence in depressed subjects Depressed subjects with alcohol
Lindsay French PGY3 Depression often comorbid with alcohol dependence 1.6x higher rate of alcohol dependence in depressed subjects Depressed subjects with alcohol dependence have complicated course of
More informationManagement of high risk MMT patients. Meldon Kahan MD Methadone Prescribers Conference Toronto, Nov 15, 2013
Management of high risk MMT patients Meldon Kahan MD Methadone Prescribers Conference Toronto, Nov 15, 2013 CFPC CoI Templates: Slide 1 Faculty Disclosure Faculty: Meldon Kahan Relationships with commercial
More informationPharmacotherapy for Tobacco Dependence Treatment
Pharmacotherapy for Tobacco Dependence Treatment Nancy Rigotti, MD Professor of Medicine, Harvard Medical School Director, Tobacco Research and Treatment Center, Massachusetts General Hospital nrigotti@partners.org
More informationAddiction Medicine: What s new for primary care
Addiction Medicine: What s new for primary care Dan Vinson, MD Family and Community Medicine How to talk so our patients listen, and listen so our patients talk. 1 2 Comfortably engaging your patient in
More informationICCAM platform. Introduction. David Nutt November 2011
ICCAM platform Introduction David Nutt November 2011 The ICCAM Platform New Drugs to Treat Addiction: Can a Knowledge of Brain Mechanisms Help? An MRC addiction cluster Imperial College London: David Nutt
More informationThe Maudsley Prescribing Guidelines in
The Maudsley Prescribing Guidelines in 11th Edition David Taylor Director of Pharmacy and Pathology South London and Maudsley NHS Foundation Trust; Professor King's College London, London, UK Paton Chief
More informationPsychosocial interventions for cannabis use disorder
Psychosocial interventions for cannabis use disorder Peter Gates 1, Pamela Sabioni 2, Jan Copeland 1, Bernard Le Foll 2, & Linda Gowing 3 1 NCPIC, UNSW Medicine; 2 Centre for Addiction and Mental Health,
More informationNeuroscience of Drug Dependence: Influence on Crime and Punishment
Neuroscience of Drug Dependence: Influence on Crime and Punishment Thomas Kosten MD JH Waggoner Chair & Professor of Psychiatry, Pharmacology & Neuroscience Associate Dean for Clinical Research Baylor
More informationUnit 1. Behavioral Health Course. ICD-10-CM Specialized Coding Training. For Local Health Departments and Rural Health
ICD-10-CM Specialized Coding Training http://publichealth.nc.gov/lhd/icd10/training.htm Behavioral Health Course For Local Health Departments and Rural Health Unit 1 1 Behavioral Health Training Objectives
More informationAlcohol And Mood Disorders. L.E. Smit, MD, FRCPC. Objectives. February 8, 2007
Alcohol And Mood Disorders L.E. Smit, MD, FRCPC February 8, 2007 1 Objectives To provide an overview of mood and anxiety disorders and alcohol use disorders. Their prevalence co-morbidity and treatment.
More informationPD ExpertBriefing: Impulsive and Compulsive Behaviors in Parkinson s Disease
PD ExpertBriefing: Impulsive and Compulsive Behaviors in Parkinson s Disease Presented By: Daniel Weintraub, M.D. Associate Professor of Psychiatry, University of Pennsylvania; Parkinson s Disease and
More informationCHCS. Multimorbidity Pattern Analyses and Clinical Opportunities: Drug and Alcohol Disorders. Center for Health Care Strategies, Inc.
CHCS Center for Health Care Strategies, Inc. FACES OF MEDICAID DATA SERIES Multimorbidity Pattern Analyses and Clinical Opportunities: Drug and Alcohol Disorders December 2010 Cynthia Boyd, MD, MPH* Bruce
More informationAn Evolving Perspective on Smoking Cessation Therapies
An Evolving Perspective on Smoking Cessation Therapies Andrew Pipe, CM, MD Chief, Division of Prevention & Rehabilitation University of Ottawa Heart Institute Faculty/Presenter Disclosure Andrew Pipe,
More informationMotivational Interviewing in MMT
Motivational Interviewing in MMT 2015 Ontario Methadone Prescribers Conference November 6 th, 2015 8:30 am 9:15 am Dr. Peter Selby, MBBS, CCFP, FCFP, MHSc, dipabam Professor, DFCM, Psychiatry and the Dalla
More informationConor K Farren. St Patricks University Hospital Trinity College Dublin Ireland
Conor K Farren St Patricks University Hospital Trinity College Dublin Ireland NICE: Background NICE set up in 1999 to reduce variation in availability and quality of NHS treatments. Does this by: Evidence
More informationIDDT Fidelity Action Planning Guidelines
1a. Multidisciplinary Team IDDT Fidelity Action Planning Guidelines Definition: All clients targeted for IDDT receive care from a multidisciplinary team. A multi-disciplinary team consists of, in addition
More informationUMASS TOBACCO TREATMENT SPECIALIST CORE TRAINING
UMASS TOBACCO TREATMENT SPECIALIST CORE TRAINING Course Description Goals and Learning Objectives 55 Lake Ave North, Worcester, MA 01655 www.umassmed.edu/tobacco 1 Table of Contents Determinants of Nicotine
More informationHealth Systems and Addiction: Provider Issues
Health Systems and Addiction: Provider Issues The Emerging Roles of Primary Care Patrick G. O Connor MD, MPH Dan and Amanda Adams Professor of General Medicine Chief, General Internal Medicine Yale University
More informationUpdate on Medications for Tobacco Cessation
Update on Medications for Tobacco Cessation Marc Fishman MD Johns Hopkins University Dept of Psychiatry Maryland Treatment Centers Baltimore MD MDQuit Best Practices Conference Jan 2013 Nicotine Addiction
More informationCO-OCCURRING DISORDERS: The Epidemiology, Conceptual Issues & A Pragmatic Approach to Treatment. Sunil Khushalani, MD 7 th November 2015
CO-OCCURRING DISORDERS: The Epidemiology, Conceptual Issues & A Pragmatic Approach to Treatment Sunil Khushalani, MD 7 th November 2015 CASE EXAMPLE-1 63 year old white male Recurrent major depression
More informationMy Mask. I keep it all inside. Because I d rather. The pain destroy me. Than everyone else. Anon.
My Mask KL I keep it all inside Because I d rather The pain destroy me Than everyone else. Anon. 43 K. N. Roy Chengappa, M.D., FRCPC Professor of Psychiatry, University of Pittsburgh School of Medicine,
More informationProject TEACH Addressing Tobacco Treatment for Pregnant Women Jan Blalock, Ph.D.
Project TEACH Addressing Tobacco Treatment for Pregnant Women Jan Blalock, Ph.D. Prevalence of Smoking and Cessation During Pregnancy In 2014, 14% in women with Medicaid coverage versus 3.6% of women with
More informationProject ECHO Importance of Treating Tobacco Use In People With Behavioral Health Disorders Jan Blalock, Ph.D.
Project ECHO Importance of Treating Tobacco Use In People With Behavioral Health Disorders Jan Blalock, Ph.D. High Levels Of Tobacco Use Almost twice as likely to smoke as people without disorders (36.1%
More informationADHD and Substance Use Disorders: An Intoxicating Combination
ADHD and Substance Use Disorders: An Intoxicating Combination Timothy E. Wilens, MD Chief, Division of Child & Adolescent Psychiatry Director, Center for Addiction Medicine Massachusetts General Hospital
More information